🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Louis Moore Bacon’s AVLN Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+110,451 Shares
Current Position
110,451 Shares
$3.64 M Value

Louis Moore Bacon's AVLN Position Overview

Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 110,451 shares of Avalyn Pharma Inc. (AVLN) worth $3.64 M, representing 0.05% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Louis Moore Bacon has initiated a new position in AVLN, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Louis Moore Bacon's Avalyn Pharma (AVLN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Avalyn Pharma (AVLN) Trades by Louis Moore Bacon

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +110,451 New Buy 110,451 $32.92

Louis Moore Bacon's Avalyn Pharma Investment FAQs

Louis Moore Bacon first purchased Avalyn Pharma Inc. (AVLN) in Q2 2026, acquiring 110,451 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Louis Moore Bacon has held Avalyn Pharma Inc. (AVLN) for 1 quarters since Q2 2026.

Louis Moore Bacon's largest addition to Avalyn Pharma Inc. (AVLN) was in Q2 2026, adding 110,451 shares worth $3.64 M.

According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 110,451 shares of Avalyn Pharma Inc. (AVLN), valued at approximately $3.64 M.

As of the Q2 2026 filing, Avalyn Pharma Inc. (AVLN) represents approximately 0.05% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.

Louis Moore Bacon's peak holding in Avalyn Pharma Inc. (AVLN) was 110,451 shares, as reported at the end of Q2 2026.